DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC)

被引：0
|
作者：
Park, S. H. [1 ]
Castellano, D. [2 ]
Petrylak, D. P. [3 ]
Galsky, M. D. [4 ]
van der Heijden, M. S. [5 ]
Loriot, Y. [6 ]
Ogawa, O. [7 ]
Su, W-P. [8 ]
Huang, W. [9 ]
Levin, W. [9 ]
Ferro, S. [9 ]
Ben, Y. [9 ]
Bellmunt, J. [10 ]
Powles, T. [11 ]
机构：
[1] Samsung Med Ctr, Dept Med, Seoul, South Korea
[2] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[3] Yale Univ, Dept Med, New Haven, CT 06520 USA
[4] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA
[5] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[6] Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[7] Kyoto Univ, Dept Urol, Kyoto, Japan
[8] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan
[9] AstraZeneca, Global Med Dev, Gaithersburg, MD USA
[10] Harvard Med Sch, Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA USA
[11] Queen Mary Univ London, Barts Canc Inst, Expt Canc Med Ctr, London, England
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
285TiP
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE
    Powles, Thomas
    Galsky, Matt D.
    Castellano, Daniel
    Van Der Heijden, Michiel Simon
    Petrylak, Daniel Peter
    Armstrong, Jon
    Belli, Riccardo
    Ferro, Salvatore
    Ben, Yong
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Global, Phase 3 study of first-line durvalumab (MEDI4736) + tremelimumab vs standard of care platinum-based chemotherapy in advanced/metastatic NSCLC: NEPTUNE
    Mok, T.
    Schmid, P.
    de Castro, G., Jr.
    Syrigos, K.
    Martin, C.
    Yamamoto, N.
    Aren, O.
    Arrieta, O.
    Gottfried, M.
    Jazieh, A. R.
    Ramlau, R.
    Timcheva, C.
    Trani, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC
    Peters, S.
    Antonia, S.
    Goldberg, S. B.
    Heymach, J. V.
    Kim, E. S.
    Nakagawa, K.
    Papadimitrakopoulou, V.
    Mukhopadhyay, P.
    McIntosh, S.
    Rizvi, N. A.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S139 - S140
  • [4] NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC
    Mok, T.
    Schmidt, P.
    Aren, O.
    Arrieta, O.
    Gottfried, M.
    Jazieh, A. R.
    Ramlau, R.
    Timcheva, K.
    Martin, C.
    McIntosh, S.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S140 - S141
  • [5] Phase 3, randomised, open-label study of durvalumab (MEDI4736) in combination with tremelimumab versus platinum-based chemotherapy in first-line treatment of patients with advanced or metastatic NSCLC: NEPTUNE
    Mok, T.
    Schmid, P.
    Aren, O.
    Arrieta, O.
    Gottfried, M.
    Jazieh, A. R.
    Ramlau, R.
    Timcheva, C.
    Martin, C.
    Zhao, L.
    McIntosh, S.
    ANNALS OF ONCOLOGY, 2015, 26 : 147 - 147
  • [6] A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)
    Powles, T. B.
    van der Heijden, M. S.
    Castellano Gauna, D.
    Loriot, Y.
    Galsky, M. D.
    Petrylak, D. P.
    Ogawa, O.
    Park, S. H.
    Necchi, A.
    Lee, J-L.
    De Giorgi, U.
    Boegemann, M.
    Bamias, A.
    Fay, A. P.
    Duran, I.
    Angra, N.
    Gupta, A. K.
    He, P.
    Levin, W.
    Bellmunt, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S550 - S551
  • [7] A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in combination with tremelimumab and SOC chemotherapy versus SOC chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).
    Galsky, Matt D.
    Necchi, Andrea
    Sridhar, Srikala S.
    Ogawa, Osamu
    Angra, Natasha
    Hois, Stephan
    He, Philip
    Ghiorghiu, Dana C.
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] A phase Ill, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).
    Galsky, Matt D.
    Necchi, Andrea
    Sridhar, Srikala S.
    Ogawa, Osamu
    Ruscica, Dario
    Angra, Natasha
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [9] A Phase III Study of MEDI4736 (M) an Anti-PD-L1 Antibody ± Tremelimumab (T), vs Standard of Care (SoC), in Patients with Advanced NSCLC (ARCTIC)
    Planchard, David
    Shtivelband, Mikhail
    Levy, Benjamin P.
    Hussein, Maen
    Shi, Kelvin
    Ibrahim, Ramy
    Ballas, Marc
    Soria, Jean-Charles
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S429 - S429
  • [10] Phase 3 study of durvalumab (MEDI4736) alone or in combination with tremelimumab versus standard of care (SoC) in platinum-resistant recurrent ormetastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): EAGLE
    Licitra, L.
    Even, C.
    Haddad, R.
    Tahara, M.
    Goswami, T.
    Franks, A.
    Emeribe, U.
    Jarkowski, A., III
    Melillo, G.
    Ferris, R. L.
    ANNALS OF ONCOLOGY, 2015, 26 : 101 - 101
12345